Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Divi's Laboratories Q3 results preview: Revenue likely to increase 25-30%

Revenue growth is likely to be aided by higher contribution from molnupiravir, an oral anti-viral treatment for COVID-19

February 04, 2022 / 08:03 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Hyderabad-based drug maker Divi’s Laboratories is expected to report robust year-on-year growth in consolidated net profit when it declares its third quarter earnings on Friday, February 4.

A higher contribution from molnupiravir, an oral anti-viral treatment for COVID-19, and nutraceuticals, or nutritional supplements, as well as strong traction in contract manufacturing are expected to aid the growth.

Revenue is likely to grow 25-30 percent on year and 7-11 percent on a sequential basis in the December quarter.

Profit is forecast to be between Rs 610 and Rs. 700 crore during the quarter. On a sequential basis it is expected to improve between 1 percent and 10 percent.